In afternoon trade, the ASX 200 stock is up 16% to $1.70. Investors have been buying the medical device company's shares ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

A new model of tiny human ovary organoids, or ovaroids, has been developed from stem cells, according to research presented ...

The human brain is known to contain a wide range of cell types, which have different roles and functions. The processes via ...

The scope of the presented studies is somewhat limited, as they primarily focus on evaluating the phenotypic changes in cardiac innervation following the loss of various Slit or Robo genes.

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

From connectors and containers to plasmids and platforms, companies work to get these treatments to patients faster and more ...

Research and development expenses for the first quarter of 2025 increased to $9.1 million from $7.7 million for the prior ...

The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109 ...

Fulcrum Therapeutics, Inc. ( NASDAQ: FULC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – ...

One in three Americans is likely to be affected by a brain disorder in their lifetime. Many of these conditions, such as ...